News from the healthcare data industry
DURHAM, N.C., March 8, 2022 /PRNewswire/ — A new TARGET-IBD study analysis shows one-third of patients with inflammatory bowel disease (IBD) did not have a record of objective disease activity assessment or therapeutic...
AI-driven discovery platform enables new way to find novel pathways as well as progress towards identifying patients who may better respond to drugs in the clinic Preclinical data highlights the...
March 08, 2022 08:00 AM Eastern Standard Time CAMBRIDGE, Mass. & NEW YORK–(BUSINESS WIRE)–Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, and Aetion, a global real-world evidence...
TUESDAY MARCH 8TH, 2022 Those without boosters nearly two times more likely to get COVID-19 during Omicron surge, with greater risk for those with co-morbidities BELLEVUE, Wash.– March 8, 2022...
Austin, Tx., McLean, Va., & Bedford, Mass., March 8, 2022—MITRE has joined Capital Factory’s Innovation Council (IC), which connects the world’s largest companies with the most innovative startups across Texas. MITRE will support...
March 08, 2022 08:45 AM Eastern Standard Time MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–DNAnexus, Inc., a leading provider of cloud-based biomedical data analysis software serving the life sciences community, today announced a...
Ariel D Stern 1, Jan Brönneke 2, Jörg F Debatin 2, Julia Hagen 2, Henrik Matthies 2, Smit Patel 3, Ieuan Clay 4, Bjoern Eskofier 5, Annika Herr 6, Kurt Hoeller 7, Ashley Jaksa 8, Daniel B Kramer 9, Mattias Kyhlstedt 10, Katherine T Lofgren 11, Nirosha Mahendraratnam 12, Holger Muehlan 13, Simon Reif 14, Lars Riedemann 15, Jennifer C Goldsack 3 Affiliations 1Technology and Operations Management...
Abstract Osteoarthritis is a degenerative joint disease that affects millions of people worldwide. Current guidelines emphasize the importance of regular physical activity as a preventive measure against disease progression and...
ABSTRACT BACKGROUND: Disparities in access, utilization and outcomes exist throughout the healthcare system for minority groups, including racial and ethnic minorities; these disparities have wide-reaching implications for individuals as well...
Treatment with eribulin (Halaven) elicited an estimated 2-year overall survival (OS) rate of 53.6% (95% CI, 35.1%-68.9%) for patients with metastatic breast cancer (MBC) previously treated with atezolizumab (Tecentriq) or...